Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Targeting Social Function in Anxiety and Eating Disorders
NCT06198023
Recruiting
Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task.... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/21/2025
Locations: UT Southwestern Multispecialty Psychiatry Clinic, Dallas, Texas
Conditions: Eating Disorders, Anorexia Nervosa, Bulimia Nervosa, Atypical Anorexia Nervosa, Purging (Eating Disorders), Other Specified Feeding or Eating Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Register for Updates
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
NCT06130254
Recruiting
Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancers
Register for Updates
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/21/2025
Locations: Univ of Texas Southwest Med Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
NCT05454488
Recruiting
To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Deliver-EE: Evaluating Effects of Meal Delivery
NCT05357261
Recruiting
This study will randomly assign 2,300 older adults on waiting lists at fourteen Meals on Wheels programs in Florida, Illinois, Maryland, Tennessee, Texas, North Carolina, South Carolina, and California into two groups who will receive: (a) daily delivery of meals, five days a week or (b) a shipment of 10 frozen meals, every two weeks. Researchers will examine participants' Medicare claims to understand if differences in healthcare utilization occur between the two groups within six months after... Read More
Gender:
ALL
Ages:
66 years and above
Trial Updated:
04/21/2025
Locations: Visiting Nurse Association of Texas, Dallas, Texas
Conditions: Healthy
Register for Updates
STOP AF First Post-Approval Study
NCT05227053
Recruiting
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Texas Health Research and Education Institute, Dallas, Texas
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Embolization of the Splenic Artery After Trauma
NCT05128955
Recruiting
Our aim is to conduct a multi-center, Bayesian, randomized clinical trial to evaluate the primary technical success of coils and vascular plugs for proximal splenic artery embolization in the setting of high-grade splenic trauma. The investigator has previously demonstrated the feasibility of such a study in a single center pilot trial.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/21/2025
Locations: The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas
Conditions: High-grade Splenic Injuries
Register for Updates
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT05039801
Recruiting
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma
Register for Updates
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489
Recruiting
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
Register for Updates
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
NCT04635891
Recruiting
The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. M... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/21/2025
Locations: Austin Neuromuscular Center, Austin, Texas
Conditions: FSHD
Register for Updates
Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines
NCT04595422
Recruiting
This implementation study will examine the best ways to refer heavy smokers to information about lung cancer screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lung Carcinoma
Register for Updates
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
NCT04493138
Recruiting
This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm
Register for Updates